Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 5e. TASK NUMBER 5f. WORK UNIT NUMBER
REPORT DATE
01-04-2006
REPORT TYPE
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERLa Jolla Institute for Molecular Medicine San Diego, CA 92121
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.
ABSTRACTThe walls of neovascular capillaries in prostate cancer are composed of endothelial cells and pericytes. Pericytes of postnatal pathological neovascularization have dual origin: They derive from bone marrow progenitors (vasculogenesis),or by sprouting from pre-existing vessels (angiogenesis). NG2+ nascent pericytes promote neovascularization and increase interstitial fluid pressure in tumors. The aims of this investigation are to determine whether therapeutic interference with pericyte-NG2 proteoglycan decreases prostate cancer neovascularization, and controls tumor growth. The anti-angiogenic effect of hydron pellets containing NG2 neutralizing antibody was quantified in intracorneal PC-3 and LNCaP xenografts. TRAMP and TRAMP-C1 tumors grafted in NG2 knockout mice represented intrinsic pericyte targeting. TRAMP and TRAMP-C1 grafts were analyzed with confocal microscope for microvascular density (MVD) and lymphatic vascular density (LVD). NG2 neutralizing antibody decreased corneal neovascularization in PC3 (p<0.0001), and LNCaP (p=0.0079) xenografts. Mean MVD in TRAMP and TRAMP-C1 tumors in NG2 knockout mice were 71% (p=0.0006) and 63% (p=0.0011) lower than wild type controls, respectively. Mean LVD in TRAMP and TRAMP-C1 tumors in NG2 knockout mice were 73% (p=0.0003) and 84% (p<0.0001) lower than wild type controls, respectively. Targeting of pericyte-NG2 decreases neovascularization , lymphangiogenesis and tumor progression in prostate cancer significantly.
SUBJECT TERMSangiogenesis, lymphatics, ...